DiaMedica Therapeutics (DMA) Stock Price, News & Analysis

Company Overview

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 27,250 shs
• Average Volume: 6,619 shs
• Market Capitalization: C$36.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:DMA
• CIK: N/A
• Web: www.diamedica.com
• Phone: +1-763-4965454
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.48
• Quick Ratio: 3.37

Sales & Book Value

• Annual Sales: C$503.66 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.33
• Book Value: C$0.17 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,856,880
• Free Float: N/A
• Market Cap: C$36.38 million
• Optionable: Not Optionable
• Beta: N/A